2019-20 Gender-based Analysis Plus

Institutional GBA+ Capacity

The PMPRB recognizes that sex and gender differences, race, ethnicity, age and mental or physical disability are factors to consider in the accessibility, affordability and appropriate use of prescription medicines and medical devices. Differences in sex and gender+ roles, income and utilization of health care services can affect access to medicines and health insurance, prescribing patterns and medicine use and may have important repercussions for health and well-being.

Since the price of a medicine does not vary for the sex or gender of the user, while the PMPRB’s price review process does not take explicit account of the diversity of user groups or their economic situation, lower medicine prices, and associated savings for all payers, will benefit all, both sex and gender+ populations directly through lower out of pocket costs and indirectly through health system reinvestments and improved access to better care. In addition, the very high-cost medicines, which will be the focus of the PMPRB’s new risk-based regulatory framework, often treat rare diseases that can impact certain minority ethnic groups disproportionately.

Highlights of GBA+ Results by Program

Patented Medicine Price Regulation Program The review of the prices of patented medicines does not consider the GBA+ of the patient taking the medicine; therefore, no initiatives are planned.
Pharmaceutical Trends Program

Trends in the prices of patented medicines do not consider the GBA+ of the patient taking the medicine; therefore, no initiatives are planned.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: